NIH stimulus to fund old grants

Rather than funding new grants, the NIH's Office of the Director will spend the vast majority of its $8.2 billion stimulus check to finance grants that have already been reviewed and to supplement existing grants. A smaller sliver -- some $100 million to $200 million -- will fund new two-year "challenge grants," which will support cutting-edge short projects, and will require researchers to report the number of jobs created or preserved by the grant to show that the money is boosting local econ

Written byElie Dolgin
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Rather than funding new grants, the NIH's Office of the Director will spend the vast majority of its $8.2 billion stimulus check to finance grants that have already been reviewed and to supplement existing grants. A smaller sliver -- some $100 million to $200 million -- will fund new two-year "challenge grants," which will support cutting-edge short projects, and will require researchers to report the number of jobs created or preserved by the grant to show that the money is boosting local economies. A new Request For Applications (RFA) is expected to be issued in the coming week or two. The NIH will also consider the geographic distribution of the grants it gives in order to target regions where the economy is especially faltering, the NIH's acting director linkurl:Raynard Kington;http://www.nih.gov/about/director/index.htm said at a news conference yesterday, according to__ linkurl:ScienceInsider.;http://blogs.sciencemag.org/scienceinsider/2009/02/nih-grant-pipel.html __Because the NIH needs to invest the stimulus money within two years, it is opting not to issue wide calls for new applications. Rather, it hopes that by backing applications already in the funding queue or injecting capital into existing research, it will be able to rapidly save and create jobs for postdocs, technicians and summer students, as well as finance the purchase of new equipment and other lab resources.
**__Related stories:__***linkurl:NIH wins stimulus jackpot;http://www.the-scientist.com/blog/display/55418/
[12th February 2009]*linkurl:How to spend the NIH stimulus;http://www.the-scientist.com/blog/display/55413/
[11th February 2009]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies